NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Erdafitinib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Histiocytosis; Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 09 Apr 2018 Planned End Date changed from 30 Mar 2021 to 31 Dec 2024.
- 09 Apr 2018 Planned primary completion date changed from 30 Mar 2021 to 31 Dec 2024.
- 21 Nov 2017 Status changed from not yet recruiting to recruiting.